scholarly journals RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

2021 ◽  
Vol 146 ◽  
pp. 74-83
Author(s):  
Umberto Malapelle ◽  
Francesco Passiglia ◽  
Chiara Cremolini ◽  
Maria Lucia Reale ◽  
Francesco Pepe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab

2013 ◽  
Vol 30 (2) ◽  
Author(s):  
Irene Guijarro-Muñoz ◽  
Antonio Sánchez ◽  
Esther Martínez-Martínez ◽  
Jose M. García ◽  
Clara Salas ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Gene Expression Profiling ◽  
Cancer Patients ◽  
Expression Profiling ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

MSI‐L/EMAST is a predictive biomarker for metastasis in colorectal cancer patients

2018 ◽  
Vol 234 (8) ◽  
pp. 13128-13136 ◽  
Author(s):  
Amir Torshizi Esfahani ◽  
Seyed Yoosef Seyedna ◽  
Ehsan Nazemalhosseini Mojarad ◽  
Ahmad Majd ◽  
Hamid Asadzadeh Aghdaei
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Predictive Biomarker ◽  
Colorectal Cancer Patients

scholarly journals Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yan Li ◽  
Yiqi Ma ◽  
Zijun Wu ◽  
Fanxin Zeng ◽  
Bin Song ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Patient Group ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Predictive Biomarker ◽  
Sensitivity Analyses ◽  
Colorectal Cancer Patients

ObjectivesFor colorectal cancer patients, traditional biomarker deficient mismatch repair/microsatellite instability (dMMR/MSI) is an accurate predictor of immune checkpoint inhibitors (ICIs). Recent years, researchers considered tumor mutation burden (TMB) as another predictive biomarker which means the number of nonsynonymous mutations in cancer cells. Several studies have proven that TMB can evaluate the efficacy of ICI therapy in diverse types of cancer, especially in non-small cell lung cancer and melanoma. However, studies on the association between TMB and the response to ICI therapy in colorectal cancer alone are still lacking. In this study, we aim to verify the effect of TMB as a biomarker in predicting the efficacy of ICIs in colorectal cancer.MethodsWe searched the PubMed and Ovid MEDLINE databases up to May 1, 2021 and screened studies for eligibility. Thirteen studies published from 2015 to 2021 with 5062 patients were included finally. We extracted and calculated hazard ratios (HRs) and odds ratios (ORs) of overall survival (OS) and objective response rates (ORRs) and their 95% confidence intervals (95% CIs). Pooled HR and OR were evaluated to compare OS and ORR between TMB-high and TMB-low groups in colorectal cancer patients. Meanwhile, we assessed heterogeneity with the I2 statistic and p-values and performed publication bias assessments, sensitivity analyses, and subgroup analyses to search the cause of heterogeneity.ResultsThe TMB-high patient group had a longer OS than the TMB-low patient group (HR = 0.68, 95% CI: 0.51, 0.92, p = 0.013) among colorectal cancer patients receiving ICIs. In addition, the TMB-high patient group was superior in terms of ORR (OR = 19.25, 95% CI: 10.06, 36.82, p < 0.001) compared to the TMB-low patient group.ConclusionsIn conclusion, this meta-analysis revealed that TMB can be used as a potential predictive biomarker of colorectal cancer patients receiving ICI therapy. Nevertheless, this finding is not stable enough. Therefore, many more randomized controlled trials are needed to prove that TMB is reliable enough to be used clinically to predict the efficacy of immunotherapy in colorectal cancer. And the most relevant biomarker remains to be determined when TMB high overlaps with other biomarkers like MSI and TILs.

Serum p53 antibodies is a postoperative predictive biomarker after curative resection in colorectal cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14567-14567
Author(s):  
A. Takeda
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Curative Resection ◽  
Predictive Biomarker ◽  
Serum Samples ◽  
P53 Antibodies ◽  
Serum P53 Antibodies ◽  
One Year ◽  
Colorectal Cancer Patients ◽  
Serum P53

14567 Background: Because alternations of the p53 tumor suppressor gene are the most commonly observed and can occur early in the carcinogenic process, the accumulation of mutant p53 often leads to the production of p53 antibodies in the sera. The aim of this study is to evaluate the clinical usefullness as early detection marker and as a predictive biomarker of serum p53 antibodies in primary colorectal cancer. Methods: Serum samples are obtained before treatment and from time to time postoperatively and stored - 800C until assay. We employed the newly produced quantitative p53 antibodies ELISA Kit (MESACUP anti-p53 Test, MBL, Japan) to determine the presence of p53 antibodies in 311 patients with colorectal adenocarcinoma compared with the conventional two markers of CEA and CA19–9. Post operative clinical course and the long time survival were evaluated in sero-positive patients after resection. Results: The sensitivities of serum p53 antibodies, CEA and CA19–9 were 32.9%, 36.0% and 23.1%, almost equivalent to CEA and significantly higher than CA19–9. No obvious correlations were evident between the status of serum p53 antibodies and values of two markers, resulting in independent of the other markers. The sensitivity rate of CEA turned up as promotion of pathological stage, but the presence of serum p53 antibodies was more significantly associated with stage 0,I,II. One hundred-nine patients who showed preoperatively sero-positive patients were monitored for at least one year after resection. There was a significant correlation between operative curability and postoperative absence of serum p53 antibodies. Most of repeatedly positive patients treated as curative resection developed recurrence within one year in stageIIandIII. Repeatedly detected patients for serum p53 antibodies have a significantly poor prognosis compared with changed negative patients after curative resection in stageIIandIII. Conclusions: Serum p53 antibodies is easy and convenient, non- invasive, detectable many times and not necessary for surgical specimens for assay. Surveillance of p53 antibodies is rapid and readily facilitated test, which appears to be useful as a new tool for early diagnosis and as a postoperative predictive marker for colorectal cancer patients. No significant financial relationships to disclose.

Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

2012 ◽  
Vol 30 (1) ◽  
Author(s):  
Esther Tahover ◽  
Beatrice Uziely ◽  
Azzam Salah ◽  
Mark Temper ◽  
Tamar Peretz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Predictive Biomarker ◽  
Bevacizumab Treatment ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document